Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Tessera Therapeutics’ Collaboration with Serotiny
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny...
Vista and Evergreen’s $16.5 Billion Acquisition of Citrix
Kirkland & Ellis and Kinstellar advised Vista, and Gibson, Dunn & Crutcher and Debevoise & Plimpton advised Evergreen. Goodwin Procter represented Citrix in the transaction. Wilson...
The Armstrong Group’s Acquisition of The Ziegenfelder Company
Goodwin advised The Ziegenfelder Company on the deal. The Ziegenfelder Company announced its sale to the Armstrong Group. Ziegenfelder, a manufacturer of frozen treats and the Budget...
Generate Biomedicines’ Research Collaboration Agreement with Amgen
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
Qualcomm and SSW Partners’ Acquisition of Veoneer
Paul, Weiss, Rifkind, Wharton & Garrison advised Qualcomm. Davis Polk & Wardwell advised SSW Partners. Skadden, Arps, Slate, Meagher & Flom and Roschier advised Veoneer on...
Merck’s $11.5 Billion Acquisition of Acceleron Pharma
Covington & Burling and Gibson, Dunn & Crutcher advised Merck, while Ropes & Gray advised Acceleron. Skadden, Arps, Slate, Meagher & Flom represented Centerview Partners LLC...
Pfizer’s $2.26 Billion Acquisition of Trillium Therapeutics
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX:...
Omega Therapeutics’ $144.6 Million IPO
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
Laronde’s $440 Million Series B Financing
Goodwin Procter advised Laronde on the deal. Laronde announced its $440 million Series B Financing to advance the development of its eRNA platform and a broad pipeline...
Cerevel Therapeutics’ $350 Million Public Offering
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...